Ali Khaki, MD, discusses results from a cost-effectiveness analysis comparing neoadjuvant immune checkpoint inhibition with cisplatin-based chemotherapy for muscle-invasive bladder cancer.
Stephen Freedland, MD, discusses study results exploring real-world evidence on survival outcomes among men who initiated ADT or ADT combined with anti-androgens, docetaxel, or abiraterone.
Ravi Jayadevappa, PhD, MS, discusses the association between hospital efficiency and quality of care in African American, Hispanic, and white Medicare beneficiaries with prostate cancer.
Sagar Patel, MD, discusses utilization trends and survival outcomes among guideline-supported treatment options in older men with high-risk prostate cancer.
Tomasz Beer, MD, discusses results from a network meta-analysis comparing the efficacy of enzalutamide vs apalutamide, darolutamide, and bicalutamide for the treatment of nonmetastatic CRPC.
Ajeet Gajra, FACP, MD, discusses differences in referral patterns and treatment preferences between medical oncologists and urologists for patients with advanced prostate cancer.
Felix Feng, MD, discusses results from exploratory analysis of the phase 3 SPARTAN trial, which investigated potential biological signatures of patients with nonmetastatic CRPC who achieved long-term responses to apalutamide and placebo.
Hala Borno, MD, discusses observations from a research study that evaluated the implementation of a clinician-facing decision tool to help promote access to clinical trials for patients with prostate cancer.
Shilpa Gupta, MD, discusses the effect of antibiotic use within 30 days of initiation of immune checkpoint inhibitors on overall survival among patients with metastatic urothelial carcinoma in real-world practice.
Vidit Sharma, MD, discusses a study exploring whether reductions in PSA screening are responsible for increased incidence of metastatic prostate cancer in the United States.
Eric Schwartz, MD, discusses results from an analysis examining out-of-pocket costs for patients with prostate cancer prescribed abiraterone or enzalutamide.
Petros Grivas, MD, PhD, discusses results from a qualitative interview study evaluating the adoption of avelumab first-line maintenance therapy as standard of care for metastatic urothelial cancer in the United States.
Shilpa Gupta, MD, discusses patient characteristics and survival outcomes by PTEN loss of function status among patients with metastatic CRPC in real-world practice.
Vidit Sharma, MD, discusses results from a cost-effectiveness analysis comparing pembrolizumab with radical cystectomy or salvage intravesical chemotherapy for patients with BCG-unresponsive carcinoma in situ of the bladder.
Daniel Lage, MD, MSc, discusses study findings showing hospitalized patients with advanced genitourinary cancers had significantly greater functional impairment and worse survival compared to those with other cancer types.
Results from a real-world study highlight the clinical and resource utilization burden of adverse events among patients with prostate cancer treated with apalutamide and enzalutamide.
Findings from a real-world study show abiraterone is associated with greater risk of cardiovascular-related hospitalizations among men with prostate cancer than enzalutamide.
Kim Chi, MD, FRCPC, discusses 4-year efficacy and safety results from the phase 3 TITAN trial, which evaluated apalutamide vs placebo in patients with metastatic castration-sensitive prostate cancer receiving ADT.
Fred Saad, MD, discusses final results from the phase 3 ACIS trial, which compared apalutamide vs placebo in combination with abiraterone acetate plus prednisone in metastatic CRPC.